Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from EMBC

Embecta Faces U.S. Reset as CEO Bets on GLP-1, Owen Mumford Diversification

Embecta (NASDAQ:EMBC) President and CEO Devdatt Kurdikar said the company’s recent U.S. business reset reflected a combination of customer-specific share loss, softer market trends and inventory-related factors, while emphasizing that the diabetes device maker is continuing a broader diversification

MarketBeat

3 Healthcare IT Stocks Revolutionizing Patient Care

With healthcare rapidly evolving through digital transformation, the demand for smarter, more efficient solutions is rising, and companies driving this shift are poised for significant upside. Therefore, investors might find opportunities in fundamentally strong healthcare IT stocks like Medtronic (MDT), McKesson Corp. (MCK), and Embecta (EMBC). Read more….

StockNews.com

3 Healthcare IT Stocks Driving Digital Transformation

The healthcare IT market is driving digital transformation by enhancing efficiency, addressing workforce shortages, and promoting personalized care, making it a promising investment sector. Therefore, strong healthcare IT stocks like Medtronic (MDT), Abbott Laboratories (ABT), and Embecta (EMBC) could be wise additions to your portfolio. Read more.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Is Embecta a Medical Device Company Worth Adding to Your Portfolio?

Driven by an increasingly prominent aging population and technological breakthroughs, the prospects of the medical devices industry are surging. So, should investors looking to capitalize on the industry’s growth prospects add Embecta (EMBC) to their portfolio? Read more….

StockNews.com

3 Healthcare Innovators Advancing Medical Technology

The healthcare industry is set for growth due to evolving healthcare demands and the rapid evolution of medical technologies. Hence, investors might consider investing in healthcare stocks, Becton, Dickinson and Co. (BDX), Zimmer Biomet Holdings (ZBH), and Embecta (EMBC). Read more….

StockNews.com

3 Medical Device Stocks With Strong Growth Prospects

The medical industry is on the fence of explosive growth, fueled by technological advancements. In this evolving landscape, investors could consider investing in promising medical device stocks like Hologic, Inc. (HOLX), Avanos Medical (AVNS), and Embecta Corp. (EMBC) with solid growth prospects. Learn more….

StockNews.com

3 High-Growth MedTech Stocks to Buy

The medtech industry’s long-term growth is fueled by growing demand for medical devices, adoption of cutting-edge technologies, and improved efficiency. Thus, it could be ideal to buy fundamentally solid medtech stocks Baxter International (BAX), Zimmer Biomet Holdings (ZBH), and Embecta (EMBC) poised for substantial growth. Keep reading.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 MedTech Stocks to Add to Your Portfolio in July

The MedTech sector’s promising future is driven by technological advances, unceasing demand for medical treatments due to an aging population, and increasing global incidence of diseases. To that end, strong MedTech stocks such as Tactile Systems Technology (TCMD), Electromed (ELMD), and Embecta (EMBC) could be wise portfolio additions in July.…

StockNews.com

3 Medical Equipment Stocks to Buy for a Healthy Portfolio

Increased chronic diseases, rising health awareness, and technological developments are poised to keep the medical equipment industry buoyed for the long term. Therefore, medical equipment stocks STERIS plc (STE), Embecta Corp. (EMBC), and Avanos Medical (AVNS), with noteworthy fundamentals, could be solid buys for a healthy portfolio. Read on….

StockNews.com

Why This Analyst Feels It's Time To Short Embecta

Despite being a market leader in insulin pen needles and syringes, Embecta Corp (NASDAQ: EMBC) may face challenges ahead, since the markets are already mature and the company has not diversified, according to BofA Securities.

Benzinga

Why Embecta Shares Are Falling Today

Becton Dickinson and Co's (NYSE:BDX) pure-play diabetes spin-off Embecta Corp (NASDAQ:EMBC) has reported Q2 sales of $274.5 million, down 3.4% on a reported basis, down 1.3% on a constant currency basis. Of the decrease, $6.0 million was attributable to unfavorable effects from foreign currency translation. Volume unfavorably impacted revenues by approximately $3.7 million, primarily…

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.